Banco Bilbao Vizcaya Argentaria S.A. Reduces Position in Align Technology, Inc. $ALGN

Banco Bilbao Vizcaya Argentaria S.A. decreased its holdings in shares of Align Technology, Inc. (NASDAQ:ALGN) by 13.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,988 shares of the medical equipment provider’s stock after selling 633 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Align Technology were worth $755,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in Align Technology by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider’s stock valued at $1,341,031,000 after acquiring an additional 185,187 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Align Technology by 12.7% during the first quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider’s stock valued at $193,764,000 after purchasing an additional 137,553 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Align Technology by 32.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock worth $132,221,000 after purchasing an additional 202,616 shares during the last quarter. Navera Investment Management Ltd. grew its holdings in shares of Align Technology by 3.0% in the second quarter. Navera Investment Management Ltd. now owns 787,559 shares of the medical equipment provider’s stock worth $149,126,000 after purchasing an additional 23,080 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in Align Technology by 0.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 736,635 shares of the medical equipment provider’s stock worth $117,022,000 after buying an additional 4,789 shares during the period. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Align Technology Stock Performance

Shares of Align Technology stock opened at $132.61 on Tuesday. The company has a market capitalization of $9.51 billion, a PE ratio of 25.70, a P/E/G ratio of 1.49 and a beta of 1.84. The company has a 50-day simple moving average of $132.83 and a two-hundred day simple moving average of $158.73. Align Technology, Inc. has a one year low of $122.00 and a one year high of $246.19.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share for the quarter, beating analysts’ consensus estimates of $2.38 by $0.23. The business had revenue of $995.69 million for the quarter, compared to analysts’ expectations of $980.75 million. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The company’s revenue was up 1.8% compared to the same quarter last year. During the same period last year, the business earned $2.35 EPS. Align Technology has set its Q4 2025 guidance at EPS. On average, equities analysts predict that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Align Technology declared that its Board of Directors has initiated a share repurchase program on Tuesday, August 5th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ALGN shares. Needham & Company LLC reissued a “hold” rating on shares of Align Technology in a research report on Thursday, October 30th. Morgan Stanley boosted their price target on Align Technology from $142.00 to $154.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group increased their price objective on Align Technology from $140.00 to $155.00 in a research note on Thursday, October 30th. Leerink Partners raised their price objective on Align Technology from $172.00 to $189.00 in a report on Thursday, October 30th. Finally, HSBC upped their target price on Align Technology from $140.00 to $150.00 in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $175.45.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.